4 reports of this reaction
1.5% of all AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE reports
#15 most reported adverse reaction
APPLICATION SITE RASH is the #15 most commonly reported adverse reaction for AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE, manufactured by Kenvue Brands LLC. There are 4 FDA adverse event reports linking AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE to APPLICATION SITE RASH. This represents approximately 1.5% of all 273 adverse event reports for this drug.
Patients taking AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE who experience application site rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
APPLICATION SITE RASH is a less commonly reported adverse event for AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE, but still significant enough to appear in the safety profile.
In addition to application site rash, the following adverse reactions have been reported for AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE:
The following drugs have also been linked to application site rash in FDA adverse event reports:
APPLICATION SITE RASH has been reported as an adverse event in 4 FDA reports for AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
APPLICATION SITE RASH accounts for approximately 1.5% of all adverse event reports for AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE, making it a notable side effect.
If you experience application site rash while taking AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.